Physician profile
John J Wolf
NPI 1689666737
$7,901.37
in general payments reported to CMS, 2019-2025
51 companies · $1,715 in 2025
The $1,715 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $860 · 2020: $161 · 2021: $953 · 2022: $1,022 · 2023: $1,510 · 2024: $1,681 · 2025: $1,715.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,906.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,905.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $708.67 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $595.88 | 2020-2025 | Vraylar, Qulipta |
| Amgen INC. | $500.41 | 2019-2025 | Evenity, Otezla, Repatha |
| Otsuka America Pharmaceutical, INC. | $434.19 | 2023-2025 | Rexulti, Nuedexta |
| Pfizer INC. | $416.22 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $401.09 | 2019-2025 | Spravato |
| Glaxosmithkline, LLC. | $359.89 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Novo Nordisk INC | $354.96 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $350.42 | 2019-2025 | Ofev, Jardiance |
| Axsome Therapeutics, INC. | $301.48 | 2024-2025 | Auvelity |
| Merck Sharp & Dohme LLC | $291.21 | 2019-2025 | Verquvo, Gardasil 9, Vaxneuvance |
| Lilly USA, LLC | $236.12 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| E.R. Squibb & Sons, L.L.C. | $226.47 | 2020-2025 | Eliquis, Camzyos |
| Antares Pharma, INC. | $224.16 | 2021-2024 | Xyosted, Tlando, Nocdurna |
| Teva Pharmaceuticals USA, INC. | $191.90 | 2019-2025 | Austedo Xr, Airduo Digihaler |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Wolf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.